ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor

  1. Zineb Mounir
  2. Joshua M Korn
  3. Thomas Westerling
  4. Fallon Lin
  5. Christina A Kirby
  6. Markus Schirle
  7. Gregg McAllister
  8. Greg Hoffman
  9. Nadire Ramadan
  10. Anke Hartung
  11. Yan Feng
  12. David Randal Kipp
  13. Christopher Quinn
  14. Michelle Fodor
  15. Jason Baird
  16. Marie Schoumacher
  17. Ronald Meyer
  18. James Deeds
  19. Gilles Buchwalter
  20. Travis Stams
  21. Nicholas Keen
  22. William R Sellers
  23. Myles Brown
  24. Raymond A Pagliarini  Is a corresponding author
  1. Genentech, United States
  2. Novartis Institutes for BioMedical Research, United States
  3. Harvard Medical School, United States
  4. Novartis Institutes for Biomedical Research, United States
  5. Organovo, United States
  6. NIBR, United States
  7. Laboratoires Servier, France
  8. Celgene Avilomics Research, United States

Abstract

The TMPRSS2:ERG gene fusion is common in androgen receptor (AR) positive prostate cancers, yet its function remains poorly understood. From a screen for functionally relevant ERG interactors, we identify the arginine methyltransferase PRMT5. ERG recruits PRMT5 to AR-target genes, where PRMT5 methylates AR on arginine 761. This attenuates AR recruitment and transcription of genes expressed in differentiated prostate epithelium. The AR-inhibitory function of PRMT5 is restricted to TMPRSS2:ERG-positive prostate cancer cells. Mutation of this methylation site on AR results in a transcriptionally hyperactive AR, suggesting that the proliferative effects of ERG and PRMT5 are mediated through attenuating AR's ability to induce genes normally involved in lineage differentiation. This provides a rationale for targeting PRMT5 in TMPRSS2:ERG positive prostate cancers. Moreover, methylation of AR at arginine 761 highlights a mechanism for how the ERG oncogene may coax AR towards inducing proliferation versus differentiation.

Article and author information

Author details

  1. Zineb Mounir

    Genentech, South San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Joshua M Korn

    Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Thomas Westerling

    Department of Medical Oncology, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Fallon Lin

    Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Christina A Kirby

    Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Markus Schirle

    Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Gregg McAllister

    Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Greg Hoffman

    Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Nadire Ramadan

    Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Anke Hartung

    Organovo, San Diego, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Yan Feng

    Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. David Randal Kipp

    Oncology, NIBR, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Christopher Quinn

    Oncology, NIBR, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Michelle Fodor

    Oncology, NIBR, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Jason Baird

    Oncology, NIBR, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Marie Schoumacher

    Laboratoires Servier, Neuilly-sur-Seine, France
    Competing interests
    The authors declare that no competing interests exist.
  17. Ronald Meyer

    Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  18. James Deeds

    Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  19. Gilles Buchwalter

    Celgene Avilomics Research, Bedford, United States
    Competing interests
    The authors declare that no competing interests exist.
  20. Travis Stams

    Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  21. Nicholas Keen

    Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  22. William R Sellers

    Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  23. Myles Brown

    Department of Medical Oncology, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  24. Raymond A Pagliarini

    Celgene Avilomics Research, Bedford, United States
    For correspondence
    raymond.pagliarini@novartis.com
    Competing interests
    The authors declare that no competing interests exist.

Copyright

© 2016, Mounir et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,039
    views
  • 1,048
    downloads
  • 63
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zineb Mounir
  2. Joshua M Korn
  3. Thomas Westerling
  4. Fallon Lin
  5. Christina A Kirby
  6. Markus Schirle
  7. Gregg McAllister
  8. Greg Hoffman
  9. Nadire Ramadan
  10. Anke Hartung
  11. Yan Feng
  12. David Randal Kipp
  13. Christopher Quinn
  14. Michelle Fodor
  15. Jason Baird
  16. Marie Schoumacher
  17. Ronald Meyer
  18. James Deeds
  19. Gilles Buchwalter
  20. Travis Stams
  21. Nicholas Keen
  22. William R Sellers
  23. Myles Brown
  24. Raymond A Pagliarini
(2016)
ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor
eLife 5:e13964.
https://doi.org/10.7554/eLife.13964

Share this article

https://doi.org/10.7554/eLife.13964

Further reading

    1. Cancer Biology
    2. Neuroscience
    Jeffrey Barr, Austin Walz ... Paola D Vermeer
    Research Article

    Cancer patients often experience changes in mental health, prompting an exploration into whether nerves infiltrating tumors contribute to these alterations by impacting brain functions. Using a mouse model for head and neck cancer and neuronal tracing, we show that tumor-infiltrating nerves connect to distinct brain areas. The activation of this neuronal circuitry altered behaviors (decreased nest-building, increased latency to eat a cookie, and reduced wheel running). Tumor-infiltrating nociceptor neurons exhibited heightened calcium activity and brain regions receiving these neural projections showed elevated Fos as well as increased calcium responses compared to non-tumor-bearing counterparts. The genetic elimination of nociceptor neurons decreased brain Fos expression and mitigated the behavioral alterations induced by the presence of the tumor. While analgesic treatment restored nesting and cookie test behaviors, it did not fully restore voluntary wheel running indicating that pain is not the exclusive driver of such behavioral shifts. Unraveling the interaction between the tumor, infiltrating nerves, and the brain is pivotal to developing targeted interventions to alleviate the mental health burdens associated with cancer.

    1. Cancer Biology
    Anne Fajac, Iva Simeonova ... Franck Toledo
    Research Article

    The Trp53 gene encodes several isoforms of elusive biological significance. Here, we show that mice lacking the Trp53 alternatively spliced (AS) exon, thereby expressing the canonical p53 protein but not isoforms with the AS C-terminus, have unexpectedly lost a male-specific protection against Myc-induced B-cell lymphomas. Lymphomagenesis was delayed in Trp53+/+Eμ-Myc males compared to Trp53ΔAS/ΔAS Eμ-Myc males, but also compared to Trp53+/+Eμ-Myc and Trp53ΔAS/ΔAS Eμ-Myc females. Pre-tumoral splenic cells from Trp53+/+Eμ-Myc males exhibited a higher expression of Ackr4, encoding an atypical chemokine receptor with tumor suppressive effects. We identified Ackr4 as a p53 target gene whose p53-mediated transactivation is inhibited by estrogens, and as a male-specific factor of good prognosis relevant for murine Eμ-Myc-induced and human Burkitt lymphomas. Furthermore, the knockout of ACKR4 increased the chemokine-guided migration of Burkitt lymphoma cells. These data demonstrate the functional relevance of alternatively spliced p53 isoforms and reveal sex disparities in Myc-driven lymphomagenesis.